KARYOPHARM THERAPEUTICS INC (KPTI)

US48576U1060 - Common Stock

1.51  +0.03 (+2.03%)

After market: 1.57 +0.06 (+3.97%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

KARYOPHARM THERAPEUTICS INC

NASDAQ:KPTI (3/28/2024, 8:20:52 PM)

After market: 1.57 +0.06 (+3.97%)

1.51

+0.03 (+2.03%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap173.76M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

KPTI Daily chart

Company Profile

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton Center, Massachusetts and currently employs 385 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is evaluating eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Company Info

KARYOPHARM THERAPEUTICS INC

85 Wells Ave

Newton Center MASSACHUSETTS 02459

P: 16176580600

CEO: Michael G. Kauffman

Employees: 385

Website: https://karyopharm.com/

KPTI News

News Image22 days ago - Karyopharm Therapeutics Inc.Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Imagea month ago - Karyopharm Therapeutics Inc.Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

News Imagea month ago - The Motley FoolKaryopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript

KPTI earnings call for the period ending December 31, 2023.

News Imagea month ago - Karyopharm Therapeutics Inc.Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

– Total Revenue of $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company's Guidance – – Top-Line...

News Imagea month ago - InvestorPlace7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.

News Imagea month ago - Karyopharm Therapeutics Inc.Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...

KPTI Twits

Here you can normally see the latest stock twits on KPTI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example